Bit Bio announces new disease models for neurological research and drug development

Nov. 24, 2022

Bit Bio Ltd. has announced the addition to its portfolio of ioGlutamatergic Neurons MAPT N279K and ioGlutamatergic Neurons MAPT P301S disease models for frontotemporal dementia (FTD), and early access to its ioGABAergic Neurons for neurological diseases, including epilepsy, schizophrenia, autism and Alzheimer's disease.

BioWorld Science Drug design, drug delivery and technologies Neurology/psychiatric

Today's news in brief

BioWorld

BioWorld briefs for Nov. 25, 2024.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for November 25, 2024.

J&J’s Ottava robotic system approved for US pivotal trial

BioWorld MedTech

Johnson & Johnson received U.S. FDA investigational device exemption to begin the pivotal clinical trial for the Ottava robotic surgical system. If the trial goes...

‘Evo’ AI can design complete genomes

BioWorld Science

The development of new machine learning tools like Alphafold and Rfdiffusion has allowed scientists to predict the structure of proteins and design them for drug...

Illustration of man holding magnifying glass to human body model showing muscle anatomy

In muscular dystrophies, gene therapies race the clock

BioWorld

Since the isolation of the gene that causes Duchenne muscular dystrophy (DMD), scientists have progressed in understanding the mechanisms that lead to muscular...

Upgrade your daily dose of biopharma and medtech news

Bit Bio announces new disease models for neurological research and drug development